Semaglutide has long been revealed to result in medullary thyroid mobile carcinoma in rodents. When its clinical relevance to individuals is unidentified, the FDA advises to not administer this drug in People with a private or household background of medullary thyroid carcinoma. Semaglutide also poses a risk of pancreatitis and dehydration.usted o